A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction

Immune dysregulation is a mechanism contributing to ineffective hematopoiesis in a subset of myelodysplastic syndrome patients. We report the first US multicenter non-randomized, phase II trial examining the efficacy of rabbit(r)-anti-thymocyte globulin using 2.5 mg/kg/day administered daily for 4 d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Komrokji, Rami S., Mailloux, Adam W., Chen, Dung-Tsa, Sekeres, Mikkael A., Paquette, Ronald, Fulp, William J., Sugimori, Chiharu, Paleveda-Pena, Jennifer, Maciejewski, Jaroslaw P., List, Alan F., Epling-Burnette, Pearlie K.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Ferrata Storti Foundation 2014
Schlagworte:
Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077078/
https://ncbi.nlm.nih.gov/pubmed/24488560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.083345
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge